What Will Happen if Millions of Americans Lose Access to GLP-1s at the Same Time?
There has never been such widespread and popularized use of compounded products due to shortages. Will consumers rise up with pitchforks if the party is shut down?
Related Articles
Impact of Patient Access to Care on Rates of Febrile Neutropenia Post Inpatient Administration of a Colony-Stimulating Factor
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Impact of a Community-Based Specialty Pharmacist in Identifying Drug Therapy Problems for New Adult Oncology Patients
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Real-World Data on Expanding Step-Up Dosing Administration of Bispecific T-Cell Engagers in the Outpatient Setting
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
ASCO 2025: Real-World Outcomes of Frontline ICI Therapy in BRAF-Mutated Melanoma in the Community Setting
Janet Espirito, PharmD, discusses real-world outcomes from a large community oncology study showing that patients with BRAF-mutated melanoma—including those with brain metastases—experienced similar benefit from…
Nitisinone Becomes First and Only FDA-Approved Treatment for HGA in Adults With AKU
Its approval was based on data from a 3-year trial that enrolled patients with alkaptonuria.
Blood Test Outperforms Tissue Biopsy in Detecting HPV+ Head and Neck Cancers
The investigational blood test achieved 99% sensitivity and specificity.
You Shall Not Pass: Pharmacist Review of Drug-Herb Interactions in Cancer Treatment
This abstract will be presented at the Oncology Pharmacists Connect (OPC) meeting in Austin, Texas, from June 19 to 20, 2025.
Understanding Biologics and Biosimilars Amid an Evolving Treatment Landscape
Biologics and biosimilars have a major role in modern medicine because of their clinical benefits and economic impact on patient care.
Enlicitide Decanoate Demonstrates Meaningful Reductions in LDL-C
In two phase 3 clinical trials, enlicitide decanoate demonstrated clinically significant reductions in low-density lipoprotein cholesterol (LDL-C) in patients with hyperlipidemia and familial hypercholesterolemia.
Study Finds Depression May Increase Risk of Developing Dementia
The authors wrote that a life course approach to the treatment and prevention of depression may help reduce individual burdens of dementia.